vs
PRIMEENERGY RESOURCES CORP（PNRG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
PRIMEENERGY RESOURCES CORP的季度营收约是REGENXBIO Inc.的1.7倍（$51.0M vs $30.3M），PRIMEENERGY RESOURCES CORP净利率更高（6.6% vs -221.3%，领先228.0%），REGENXBIO Inc.同比增速更快（43.0% vs -15.7%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 9.0%）
PrimeEnergy Resources Corp是一家独立能源企业，专注于石油与天然气的勘探、开发及生产业务，主要运营范围覆盖美国境内陆上资源盆地，面向区域能源市场供应能源产品，满足工业及民用能源需求。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PNRG vs RGNX — 直观对比
营收规模更大
PNRG
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出58.7%
-15.7%
净利率更高
PNRG
高出228.0%
-221.3%
两年增速更快
RGNX
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $51.0M | $30.3M |
| 净利润 | $3.4M | $-67.1M |
| 毛利率 | 97.9% | — |
| 营业利润率 | 3.2% | -190.0% |
| 净利率 | 6.6% | -221.3% |
| 营收同比 | -15.7% | 43.0% |
| 净利润同比 | 48.7% | -31.2% |
| 每股收益（稀释后） | $1.43 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PNRGRGNX
| Q4 25 | $51.0M | $30.3M | ||
| Q3 25 | $46.0M | $29.7M | ||
| Q2 25 | $42.0M | $21.4M | ||
| Q1 25 | $50.1M | $89.0M | ||
| Q4 24 | $60.5M | $21.2M | ||
| Q3 24 | $69.5M | $24.2M | ||
| Q2 24 | $64.8M | $22.3M | ||
| Q1 24 | $43.0M | $15.6M |
净利润PNRGRGNX
| Q4 25 | $3.4M | $-67.1M | ||
| Q3 25 | $10.6M | $-61.9M | ||
| Q2 25 | $3.2M | $-70.9M | ||
| Q1 25 | $9.1M | $6.1M | ||
| Q4 24 | $2.3M | $-51.2M | ||
| Q3 24 | $22.1M | $-59.6M | ||
| Q2 24 | $19.7M | $-53.0M | ||
| Q1 24 | $11.3M | $-63.3M |
毛利率PNRGRGNX
| Q4 25 | 97.9% | — | ||
| Q3 25 | 95.6% | — | ||
| Q2 25 | 97.1% | — | ||
| Q1 25 | 96.3% | — | ||
| Q4 24 | 98.8% | 70.2% | ||
| Q3 24 | 95.5% | 48.8% | ||
| Q2 24 | 96.2% | 52.5% | ||
| Q1 24 | 93.5% | 72.6% |
营业利润率PNRGRGNX
| Q4 25 | 3.2% | -190.0% | ||
| Q3 25 | 28.9% | -176.3% | ||
| Q2 25 | 10.0% | -296.3% | ||
| Q1 25 | 22.7% | 13.6% | ||
| Q4 24 | 6.8% | -242.1% | ||
| Q3 24 | 40.4% | -256.6% | ||
| Q2 24 | 38.1% | -251.3% | ||
| Q1 24 | 33.4% | -408.8% |
净利率PNRGRGNX
| Q4 25 | 6.6% | -221.3% | ||
| Q3 25 | 23.0% | -208.3% | ||
| Q2 25 | 7.7% | -331.8% | ||
| Q1 25 | 18.2% | 6.8% | ||
| Q4 24 | 3.8% | -241.3% | ||
| Q3 24 | 31.8% | -246.3% | ||
| Q2 24 | 30.4% | -237.7% | ||
| Q1 24 | 26.3% | -405.4% |
每股收益（稀释后）PNRGRGNX
| Q4 25 | $1.43 | $-1.30 | ||
| Q3 25 | $4.38 | $-1.20 | ||
| Q2 25 | $1.33 | $-1.38 | ||
| Q1 25 | $3.72 | $0.12 | ||
| Q4 24 | $0.97 | $-0.99 | ||
| Q3 24 | $8.80 | $-1.17 | ||
| Q2 24 | $7.77 | $-1.05 | ||
| Q1 24 | $4.41 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $215.7M | $102.7M |
| 总资产 | $323.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PNRGRGNX
| Q4 25 | $7.4M | $230.1M | ||
| Q3 25 | $3.7M | $274.2M | ||
| Q2 25 | $2.4M | $323.3M | ||
| Q1 25 | $2.1M | $267.9M | ||
| Q4 24 | $2.5M | $234.7M | ||
| Q3 24 | $1.6M | $255.5M | ||
| Q2 24 | $2.0M | $290.4M | ||
| Q1 24 | $1.8M | $338.7M |
股东权益PNRGRGNX
| Q4 25 | $215.7M | $102.7M | ||
| Q3 25 | $213.8M | $161.5M | ||
| Q2 25 | $205.2M | $213.7M | ||
| Q1 25 | $205.0M | $274.2M | ||
| Q4 24 | $202.9M | $259.7M | ||
| Q3 24 | $203.8M | $301.4M | ||
| Q2 24 | $186.3M | $348.3M | ||
| Q1 24 | $169.4M | $390.7M |
总资产PNRGRGNX
| Q4 25 | $323.9M | $453.0M | ||
| Q3 25 | $332.0M | $525.2M | ||
| Q2 25 | $343.0M | $581.0M | ||
| Q1 25 | $339.3M | $490.9M | ||
| Q4 24 | $324.6M | $466.0M | ||
| Q3 24 | $345.6M | $519.1M | ||
| Q2 24 | $334.8M | $569.4M | ||
| Q1 24 | $332.9M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 3.60× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PNRGRGNX
| Q4 25 | $12.2M | $-52.3M | ||
| Q3 25 | $54.7M | $-56.0M | ||
| Q2 25 | $-8.3M | $-49.3M | ||
| Q1 25 | $38.2M | $33.6M | ||
| Q4 24 | $23.9M | $-31.6M | ||
| Q3 24 | $50.8M | $-40.5M | ||
| Q2 24 | $-1.9M | $-45.5M | ||
| Q1 24 | $43.2M | $-55.5M |
自由现金流PNRGRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率PNRGRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度PNRGRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率PNRGRGNX
| Q4 25 | 3.60× | — | ||
| Q3 25 | 5.18× | — | ||
| Q2 25 | -2.58× | — | ||
| Q1 25 | 4.18× | 5.53× | ||
| Q4 24 | 10.50× | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | 3.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PNRG
| Oil Sales | $43.1M | 84% |
| Natural Gas Liquid | $5.5M | 11% |
| Oil And Gas Service | $2.0M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
